Google has updated and re-released open-source software for cleaning, analyzing, and transforming data sets, now called Google Refine.
The software, originally called Freebase Gridworks, came with Metaweb, a company Google purchased in July.
[ Keep up with the latest approaches to managing information overload and staying compliant in InfoWorld's Enterprise Data Explosion newsletter. ]
Google Refine is a collection of tools that could come in handy when wrangling useful information from a data set, particularly ones that have data inconsistencies.
This desktop application can, for instance, find all the variant spellings of a word in a data set and replace them with the appropriate term. This process, called normalization, is nothing new. But normalizing data usually requires writing code that is specific to one data set, noted Christopher Groskopf, a developer for the Chicago Tribune.
"The genius of Gridworks is that it is generic enough to work for a wide variety of data sets without the need to write any code at all. Even better the resulting operations are portable, so the process used to clean up 2009′s data can be repeated for 2010," Groskopf wrote in a blog post.
The software contains a number of other tools as well. It includes an expression language that can be used to analyze a set of data. Filters can be used to isolate subsets of data, which then can be analyzed or changed through a set of transform commands.
The software can work with up to a few hundred thousand rows per data set, depending on the user's computer memory. And unlike most spreadsheet software, this software can interactively transform large subsets of data, the company asserted.
Google said this week that it has added several new features to the software, officially called Google Refine 2.0, including the ability to link records to other databases, and a number of new transformation commands and expressions.
The non-profit government watchdog organization ProPublica has used this software to aggregate data from seven different data sets to show how pharmaceutical companies pay doctors to recommend certain medications.